These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 10809936)

  • 1. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors.
    Kumar V; Anand R; Messina J; Hartman R; Veach J
    Eur J Neurol; 2000 Mar; 7(2):159-69. PubMed ID: 10809936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivastigmine for Alzheimer's disease.
    Birks JS; Grimley Evans J
    Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.
    Burns A; Spiegel R; Quarg P
    Int J Geriatr Psychiatry; 2004 Mar; 19(3):243-9. PubMed ID: 15027039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon).
    Forette F; Anand R; Gharabawi G
    Eur J Neurol; 1999 Jul; 6(4):423-9. PubMed ID: 10362894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.
    Farlow M; Anand R; Messina J; Hartman R; Veach J
    Eur Neurol; 2000; 44(4):236-41. PubMed ID: 11096224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression.
    Farlow MR; Hake A; Messina J; Hartman R; Veach J; Anand R
    Arch Neurol; 2001 Mar; 58(3):417-22. PubMed ID: 11255445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivastigmine in patients with Alzheimer's disease and concurrent hypertension.
    Erkinjuntti T; Skoog I; Lane R; Andrews C
    Int J Clin Pract; 2002 Dec; 56(10):791-6. PubMed ID: 12510954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivastigmine for Alzheimer's disease.
    Birks J; Grimley Evans J; Iakovidou V; Tsolaki M; Holt FE
    Cochrane Database Syst Rev; 2009 Apr; (2):CD001191. PubMed ID: 19370562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
    Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
    Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
    Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
    Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivastigmine for Alzheimer's disease.
    Birks J; Grimley Evans J ; Iakovidou V; Tsolaki M
    Cochrane Database Syst Rev; 2000; (4):CD001191. PubMed ID: 11034705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
    Rösler M; Anand R; Cicin-Sain A; Gauthier S; Agid Y; Dal-Bianco P; Stähelin HB; Hartman R; Gharabawi M
    BMJ; 1999 Mar; 318(7184):633-8. PubMed ID: 10066203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivastigmine for vascular cognitive impairment.
    Birks J; McGuinness B; Craig D
    Cochrane Database Syst Rev; 2013 May; (5):CD004744. PubMed ID: 23728651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.
    Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B
    Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
    Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
    Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis.
    Alva G; Isaacson R; Sadowsky C; Grossberg G; Meng X; Somogyi M
    Int J Geriatr Psychiatry; 2014 Sep; 29(9):920-7. PubMed ID: 24549933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oestro-progestagen treatment combined with rivastigmine in menopausal women suffering from Alzheimer's disease. The results of a 28-weeks controlled study].
    Rigaud AS; André G; Vellas B; Touchon J; Pere JJ; Loria-Kanza Y
    Presse Med; 2003 Oct; 32(35):1649-54. PubMed ID: 14631268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.
    Karaman Y; Erdoğan F; Köseoğlu E; Turan T; Ersoy AO
    Dement Geriatr Cogn Disord; 2005; 19(1):51-6. PubMed ID: 15383747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.